PathoVax

Two pieces of great news this Mid-March! First off, PathoVax has secured another SBIR Phase 1 worth $300K from the NCI to imbue thermostable and single-dose properties into our existing RGVax HPV vaccine. This new formulation will potentiate the world’s 1st single- immunization, thermostable, broad-spectrum Human Papillomavirus (HPV) Vaccine!!

Secondly, We will be presenting long term pre-clinical protection data in a Late Breaking Abstract Poster session at the upcoming 2019 American Association for Cancer Research Annual Meeting!!!

1st Annual PathoVax Christmas Party! Special thanks to our Scientific Advisor, Prof Roden for joining us!!! ! Happy Holidays to all!!!

PathoVax closes $2.75M Series A1 round!

JHU startup PathoVax raises $2.75M, grows team - Technical.ly Baltimore The company is working toward clinical trials of its HPV vaccine.

Expanding our global outreach! We are pleased to announce that PathoVax is a 2018 Laureate in the YEi initiative program. This provides a personalized immersion week in France (including training sessions, networking and one-on-one meetings) that will allow us to benefit from an extensive customized business network and connections to the best resources in Europe.

Meet the 2018 US Laureates of the YEi Start in France Program - Office for Science & Technology of the Embassy of France in the United States The YEi Start in France program is an annual competition organized by the Ministry for Europe and Foreign Affairs for young foreign science-based companies interested in growing their business in France and Europe. Meet the 2018 US Laureates of the YEI Start in France Program.

We are honored to have received 1st Place ($100K RMB) at the 2nd China (Shenzhen) Innovation & Entrepreneurship International Competition (Boston, USA division)! Looking forward to having Weijie Poh represent us and share our vision of preventing and treating Cancers/infectious diseases at the grand finals in Shenzhen, China! #全面保护 #加油!!!!